The Fox Chase Cancer Center is under new leadership since the last review and continues as one of the nation's few free standing comprehensive cancer centers. The Center's mission is """"""""To prevail over cancer, marshaling excellence of heart and mind each day in the collaborative practice of bold scientific discovery, prevention strategies, and compassionate cancer care."""""""" Our vision is to be an acknowledged national leader in cancer research and medicine and a pre-eminent cancer center in the Philadelphia area. The new leadership in conjunction with advice from External Advisory Boards has consolidated the CCSG Research Programs from 11 to 5. These five Programs represent the core scientific strengths of the Fox Chase Cancer Center. At the last review 30 CCSG Shared Facilities and 2 support elements (Protocol Review and Monitoring System and Protocol Specific Research) were approved for funding with recommendations to consolidate facilities. This proposal requests partial support for 16 core facilities and 2 support elements. Developmental Funds are requested to strategically increase critical mass for these 5 research Programs over the CCSG funding cycle. A plan is presented to recruit 21 to 30 new and replacement investigators. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer-reviewed funding within 24 months of their appointment. Of that amount $5.1 million was garnered by investigators who were partially supported by Developmental Funds. Since the last submission, the Cancer Research Pavilion was completed as planned in 2010 and will provide much of the needed space for new investigator laboratories. The Leadership's vision includes a plan to increase team-based science via strategic keystone investments. These institutional investments are intended to expand the research portfolio of FCCC to include more """"""""team-based"""""""" grants such as Program Project Grants and SPOREs. Several team-based science grant proposals will be submitted over the next few years as a direct result of these keystone Investments. To meet the demand presented by a future increase in principal investigators, the Center plans to leverage $8 million of ARRA funds with $5.1 million of institutional investment to construct a Comparative Medical Facility (CMR). Since the last review, FCCC has implemented a formal review mechanism to evaluate and prioritize its CCSG Shared Research Resources. As a result, of this evaluation process, the number of Shared Research Resources has been streamlined.

Public Health Relevance

NCI-designated Cancer Centers such as Fox Chase Cancer Center serve as major source of discovery of the nature of cancer, and development of more effective approaches to prevention, diagnosis and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006927-50S9
Application #
8918892
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1997-07-21
Project End
2015-06-30
Budget Start
2014-09-04
Budget End
2015-06-30
Support Year
50
Fiscal Year
2014
Total Cost
$133,875
Indirect Cost
$58,875
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395

Showing the most recent 10 out of 1280 publications